Sana Biotechnology: A Small, Speculative Play
Source: SeekingAlpha
2026-02-13 03:24:54 ET
Shares of engineered cell concern Sana Biotechnology, Inc. ( SANA ) have nearly tripled off their recent lows in early April, mostly on the strength of data from one type 1 diabetes patient who received a precursor to its SC451. The clinical data not only suggest the possibility of a functional cure but also de-risk/validate its approach to escaping immune destruction, which could have applications across many indications....
Read the full article on Seeking Alpha
For further details see:
Sana Biotechnology: A Small, Speculative Play
Sana Biotechnology Inc.
NASDAQ: SANA
SANA Trading
4.86% G/L:
$3.235 Last:
1,548,561 Volume:
$3.08 Open:
SANA Latest News
March 03, 2026 04:05:00 pm
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
February 17, 2026 09:00:00 am
Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer
SANA Stock Data
$1,021,514,070
186,189,918
2.26%
60
N/A
Biotechnology & Life Sciences
Healthcare
US
Seattle
